Publications by authors named "Michael Beggs"
Background: Deficiencies in risk assessment for patients with pulmonary nodules (PNs) contribute to unnecessary invasive testing and delays in diagnosis.
Research Question: What is the accuracy of a novel PN risk model that includes plasma proteins and clinical factors? How does the accuracy compare with that of an established risk model?
Study Design And Methods: Based on technology using magnetic nanosensors, assays were developed with seven plasma proteins. In a training cohort (n = 429), machine learning approaches were used to identify an optimal algorithm that subsequently was evaluated in a validation cohort (n = 489), and its performance was compared with the Mayo Clinic model.
POST-OPERATIVE CRITERION BASED REHABILITATION OF ACL REPAIRS: A CLINICAL COMMENTARY.
Int J Sports Phys Ther
April 2018
Unlabelled: The anterior cruciate ligament (ACL) is the most commonly reconstructed ligament of the knee. Most often, the goal of surgical reconstruction is to recreate stability within the knee and prevent joint degeneration. To date, clinical studies have not demonstrated the ability of various reconstruction techniques in establishing complete knee stability when comparing rates of osteoarthritis.
View Article and Find Full Text PDFObjectives: The goal of this study is to determine the cost-effectiveness of MIRISK VP, a next generation coronary heart disease risk assessment score, in correctly reclassifying and appropriately treating asymptomatic, intermediate risk patients.
Study Design: A Markov model was employed with simulated subjects based on the Multi-Ethnic Study of Atherosclerosis (MESA). This study evaluated three treatment strategies: (i) practice at MESA enrollment, (ii) current guidelines, and (iii) MIRISK VP in MESA.
Background: Current coronary heart disease (CHD) risk assessments inadequately assess intermediate-risk patients, leaving many undertreated and vulnerable to heart attacks. A novel CHD risk-assessment (CHDRA) tool was developed for intermediate-risk stratification using biomarkers and established risk factors to significantly improve CHD risk discrimination.
Hypothesis: Physicians will change their treatment plan in response to more information about a patient's CHD risk level provided by the CHDRA test.
Article Synopsis
- Coronary heart disease (CHD) is still a widespread issue, leading researchers to create a new risk assessment algorithm called CHDRA, aimed at better evaluation for individuals at intermediate risk.
- The CHDRA includes a series of biomarker assays tested in a clinical lab to check their performance in terms of accuracy, sensitivity, and reproducibility.
- Results show that the CHDRA assays perform well, with consistency across different tests and minimal impact from common laboratory variables, indicating a reliable tool for assessing CHD risk.
Article Synopsis
- Aviir, Inc. is a biotech company focused on creating lab tests to help prevent cardiovascular diseases and metabolic syndromes through personalized information for doctors and patients.
- They developed MIRISK VP™, a test designed to assess the risk of heart attacks in individuals.
- Aviir also aims to enhance its genomic testing capabilities to identify inherited cardiovascular issues, combining various diagnostic tools for a complete health solution.